HRSA-22-017: Ryan White HIV/AIDS Program Part C Early Intervention Services Program: Limited Existing Geographic Service Areas
Closed
This grant is closed. A newer notice from the same program is forecast: Ryan White HIV/AIDS Program Part C Capacity Development Program (HRSA-27-069). Status: Expected deadline March 16, 2027. It is in our archive of Health Resources and Services Administration notices from 2021.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 5 awards worth $1.5 million in total. Applications closed on December 10, 2021.
From the official notice on Grants.gov, last changed September 30, 2021. Checked November 7, 2026.
- Total funding$1.5 million
- Expected awards5
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-25-052 | October 8, 2024 | Closed December 10, 2024 | Closed |
Key dates
| Posted | September 30, 2021 |
|---|---|
| Deadline | December 10, 2021 |
| Archived by Grants.gov | February 8, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
This competition is open to current recipients and new eligible applicants proposing to provide comprehensive primary health care and support services in outpatient settings for low income, uninsured, and underserved people with HIV in the service areas as described in Appendix B. As identified in section 2652(a)(1) of the PHS Act, the following public and non-profit private entities are eligible to apply: a) Federally-qualified health centers under section 1905(1)(2)(B) of the Social Security Act; b) Grant recipients under section 1001 of the PHS Act (regarding family planning) other than States; c) Comprehensive hemophilia diagnostic and treatment centers; d) Rural health clinics; e) Health facilities operated by or pursuant to a contract with the Indian Health Service; f) Community-based organizations, clinics, hospitals, and other health facilities that provide early intervention services to people who contracted HIV through intravenous drug use; or g) Nonprofit private entities that provide comprehensive primary care services to populations at risk of HIV, including faith-based and community-based organizations. Tribes and tribal organizations that meet the above criteria are eligible to apply.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This competition is open to current RWHAP Part C EIS recipients and new organizations proposing to provide RWHAP Part C EIS funded services in existing geographic service areas, as listed and defined in Appendix B of this announcement. RWHAP Part C EIS recipients must provide comprehensive primary health care and support services throughout the entire respective designated geographic service area (referred to as “service areas” throughout this NOFO) listed in Appendix B with the goals of providing optimal HIV care and treatment for low-income underserved people with HIV not adequately covered by other sources of support. HRSA will fund up to five service areas under this notice. Applications under HRSA-22-017 must address the entire service area, as defined in Appendix B. If you are applying for more than one service area, you must submit a separate application for each service area.
Who has won Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease grants before
From fiscal 2021 to 2025, Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease (93.918) awarded $527 million across 527 grant awards, an average of $999,367 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 10 | $10.3 million |
| Sun River Health, Inc. | New York | 2 | $4.2 million |
| Mobile County Board of Health | Alabama | 4 | $3.9 million |
| The Research Foundation for the State University of New York | New York | 2 | $3.7 million |
| Rutgers the State University of New Jersey | New Jersey | 4 | $3.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-069, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-22-017 still open?
No. It closed on December 10, 2021. A newer notice is forecast: HRSA-27-069, expected deadline March 16, 2027.
Who can apply for Ryan White HIV/AIDS Program Part C Early Intervention Services Program: Limited Existing Geographic Service Areas?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Ryan White HIV/AIDS Program Part C Early Intervention Services Program: Limited Existing Geographic Service Areas?
Closed December 10, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $1.5 million in total across about 5 awards.
Who has won Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease grants before?
The largest recipients over five fiscal years were Florida Department of Health, Sun River Health, Inc., Mobile County Board of Health. The program made 527 awards worth $527 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)